Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.79 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | PRKACA | P17612 | 4/20 | 0.79 |
| ▸ | PRKX | P51817 | 3/20 | 0.79 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.79 |
| ▸ | GSK3A | P49840 | 3/20 | 0.79 |
| ▸ | GSK3B | P49841 | 3/20 | 0.79 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | PTAFR | P25105 | 1/20 | 0.63 |
| ▸ | GRK5 | P34947 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568765 | 0.93 | RAB9A (0.69) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12495842 | 0.89 | RAB9A (0.71) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1584297 | 0.88 | ROCK2 (1.00) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25719243 | 0.85 | ROCK2 (0.93) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18085942 | 0.84 | RAB9A (0.64) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5681767 | 0.84 | RAB9A (0.73) | RAB9ACA1CA2CA7CA9 | |
| SCHEMBL16712959 | 0.83 | ROCK2 (0.77) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL95553 | 0.83 | RAB9A (0.72) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6718536 | 0.83 | RAB9A (0.72) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6713509 | 0.83 | RAB9A (0.72) | ROCK2ROCK1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617214-B2 | Compounds for cognitive enhancement and methods of use thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617214-B2 | Compounds for cognitive enhancement and methods of use thereof | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015070170-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272587-A1 | COMPOUNDS FOR COGNITIVE ENHANCEMENT AND METHODS OF USE THEREOF | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CYP3A4 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.